Specifically, Vav1 synergizes with KRAS mutations to promote pancreatic cancer, while GEF–H1 facilitates hepatocellular carcinoma (HCC) metastasis by modulating RhoA‐dependent cytoskeletal changes. The gene discussed is RHOA; the disease is hepatocellular carcinoma.